Leadership

Every year, the Board of Directors conducts a self assessment. Based on the result of this assessment, the organisation and efficiency of the Board of Directors' work are discussed at a Board meeting.

In 2026, the annual self-assessment of the Board of Directors was performed with external assistance. The self-assessment consisted of an online questionnaire in which board members as well as the Executive Leadership Team responded anonymously. On the basis of the responses received, the external advisor prepared a full Board self-assessment report which has been discussed with the external advisor and with the Board and Executive Leadership team. 

The self-assessment shows that the Board of Directors is working well as a collective in many areas but also defines certain areas for improvement. As part of the self-assessment, the Board of Directors has particularly discussed handling of strategy 
execution, cooperation between Board and Executive Leadership Team and succession planning, including required competencies. The Board of Directors has 
also concluded that the required competencies are represented at board level and that the committee structure is satisfactory. 

During the past year, the Board of Directors has spent considerable time searching for and recruiting Gavin Wood as new President & CEO of Coloplast. In addition, 
the Board of Directors has devoted significant resources in identifying a new boardmember, Niels B. Christiansen, who joined the Board in December 2025 and who will assume the role of Chairman no later than in connection with the Annual General Meeting in 2026. The Board of Directors has also prioritised time following-up on implementation of the Impact4 strategy while also discussing operational disruptions, particular due to reimbursement changes within Wound & Tissue Repair in the US. The Board of Directors has also continued monitoring integration efforts and impact on Coloplast of geopolitical events.